Overcoming challenges of HERG potassium channel liability through rational design: Eag1 inhibitors for cancer treatment.

Žan Toplak, Louise A Hendrickx, Reham Abdelaziz, Xiaoyi Shi, Steve Peigneur, Tihomir Tomašič, Jan Tytgat, Lucija Peterlin-Mašič, Luis A Pardo

Medicinal research reviews 2022 Jan

filter terms:

Two decades of research have proven the relevance of ion channel expression for tumor progression in virtually every indication, and it has become clear that inhibition of specific ion channels will eventually become part of the oncology therapeutic arsenal. However, ion channels play relevant roles in all aspects of physiology, and specificity for the tumor tissue remains a challenge to avoid undesired effects. Eag1 (KV 10.1) is a voltage-gated potassium channel whose expression is very restricted in healthy tissues outside of the brain, while it is overexpressed in 70% of human tumors. Inhibition of Eag1 reduces tumor growth, but the search for potent inhibitors for tumor therapy suffers from the structural similarities with the cardiac HERG channel, a major off-target. Existing inhibitors show low specificity between the two channels, and screenings for Eag1 binders are prone to enrichment in compounds that also bind HERG. Rational drug design requires knowledge of the structure of the target and the understanding of structure-function relationships. Recent studies have shown subtle structural differences between Eag1 and HERG channels with profound functional impact. Thus, although both targets' structure is likely too similar to identify leads that exclusively bind to one of the channels, the structural information combined with the new knowledge of the functional relevance of particular residues or areas suggests the possibility of selective targeting of Eag1 in cancer therapies. Further development of selective Eag1 inhibitors can lead to first-in-class compounds for the treatment of different cancers. © 2021 The Authors. Medicinal Research Reviews Published by Wiley Periodicals LLC.

Citation

Žan Toplak, Louise A Hendrickx, Reham Abdelaziz, Xiaoyi Shi, Steve Peigneur, Tihomir Tomašič, Jan Tytgat, Lucija Peterlin-Mašič, Luis A Pardo. Overcoming challenges of HERG potassium channel liability through rational design: Eag1 inhibitors for cancer treatment. Medicinal research reviews. 2022 Jan;42(1):183-226